BrightGene's BGM0504 Sets New Global Diabetes Benchmark: Surpasses Tirzepatide in Monotherapy and Outperforms Semaglutide Head-to-Head

By Medical Research Correspondent

A Chinese pharmaceutical company is making waves in the global diabetes treatment arena with clinical trial results that suggest its experimental drug may outperform two of the market's leading therapies. BrightGene Medicine (688166.SH), a Shanghai-listed biopharmaceutical firm, announced positive Phase III results for BGM0504, a once-weekly injectable treatment for type 2 diabetes that demonstrated superior blood sugar control compared to both tirzepatide and semaglutide—the current gold standards in diabetes care.

The results, if validated by regulatory review, could position BGM0504 as a formidable competitor in a market dominated by Eli Lilly's tirzepatide (sold as Mounjaro and Zepbound) and Novo Nordisk's semaglutide (marketed as Ozempic, Wegovy, and Rybelsus). These drugs have become blockbusters, with combined global sales exceeding $30 billion in 2023, driven by their dual role in diabetes management and weight loss.

Monotherapy Results Exceed Expectations

In a standalone Phase III trial involving 227 patients with an average baseline HbA1c of 8.3%, BGM0504 delivered what diabetes specialists describe as impressive glycemic control. After 32 weeks of treatment, patients receiving the 10 mg dose experienced an average HbA1c reduction of 2.6 percentage points. The 5 mg dose achieved a 2.2 percentage point reduction, compared to just 0.51 percentage points in the placebo group.

To put these numbers in context: tirzepatide's Chinese monotherapy trial (SURPASS-CN-MONO) showed HbA1c reductions of 2.19%, 1.75%, and 2.03% for the 5 mg, 10 mg, and 15 mg doses respectively after 40 weeks. In the global SURPASS-1 study, tirzepatide's 5 mg and 10 mg doses produced 1.75% and 1.71% reductions over the same period. Semaglutide's SUSTAIN-1 trial demonstrated 1.45% and 1.55% reductions for the 0.5 mg and 1.0 mg doses after 30 weeks.

BGM0504's 5 mg dose, which achieved a 2.2% reduction in just 32 weeks, already exceeded the numerical performance of all tirzepatide and semaglutide doses in these comparator studies. The 10 mg dose's 2.6% reduction represents the most substantial decline observed across these trials.

Target Achievement Rates Tell a Compelling Story

Beyond average reductions, the proportion of patients reaching specific HbA1c targets offers insight into clinical meaningfulness. In BGM0504's monotherapy trial, 93.4% of patients in the 10 mg group achieved HbA1c levels below 7%—the standard diabetes control threshold—while 51.8% reached the more stringent target of less than 5.7%, considered normal glycemic range. In the 5 mg group, 82.2% achieved HbA1c below 7% and 39.9% reached below 5.7%.

Comparing these achievement rates: tirzepatide's SURPASS-CN-MONO trial reported 90.4% and 79.2% of patients reaching HbA1c below 7% in the 5 mg and 10 mg groups, respectively, with 40.4% and 29.8% achieving below 5.7%. In the global SURPASS-1 study, tirzepatide's 5 mg and 10 mg doses resulted in 30.9% and 26.8% of patients reaching the strict below-5.7% target. Semaglutide's SUSTAIN-1 trial showed 74.0% and 72.0% of patients achieving below 7% for the 0.5 mg and 1.0 mg doses.

BGM0504's 10 mg dose not only achieved the highest proportion of patients reaching below 7% (93.4%), but its 51.8% achievement rate for the strict below-5.7% target exceeded tirzepatide's best performance by 11.4 percentage points.

Head-to-Head Victory Over Semaglutide

Perhaps more telling than cross-study comparisons is BGM0504's direct confrontation with semaglutide in a combination therapy trial. This Phase III study enrolled Chinese adults with type 2 diabetes whose blood sugar remained inadequately controlled on oral medications such as metformin. Patients received either BGM0504 (5 mg or 10 mg) or semaglutide 1.0 mg as add-on therapy, with the primary endpoint measured at 32 weeks.

At the 32-week primary analysis, BGM0504 10 mg demonstrated statistical superiority over semaglutide 1.0 mg. The BGM0504 group achieved an average HbA1c reduction of 2.41 percentage points, compared to 1.95 percentage points in the semaglutide group—an additional 0.46 percentage point reduction that proved statistically significant. The 5 mg dose achieved a 2.05 percentage point reduction.

This superiority persisted through 52 weeks. BGM0504 10 mg maintained a 2.34 percentage point reduction versus semaglutide's 1.88 percentage points, preserving the 0.46 percentage point advantage. The 5 mg group showed a 2.07 percentage point reduction, while semaglutide declined to 1.88 percentage points. Notably, a supplementary analysis confirmed that the 5 mg dose also achieved statistical superiority over semaglutide at 52 weeks, with an additional 0.19 percentage point reduction.

Target achievement rates in the combination therapy trial further underscored BGM0504's advantage. At 32 weeks, 85.5% of patients in the 10 mg group reached HbA1c below 7%, compared to 77.5% in the semaglutide group—an 8.0 percentage point difference. For the stricter below-5.7% target, 42.9% of BGM0504 patients succeeded versus 22.6% of semaglutide patients, a 20.3 percentage point gap.

Benchmarking Against Tirzepatide's SURPASS-2

When positioned against tirzepatide's landmark SURPASS-2 trial—which directly compared tirzepatide to semaglutide—BGM0504's combination therapy results appear competitive. In SURPASS-2, tirzepatide's 5 mg and 10 mg doses achieved 2.01 and 2.24 percentage point reductions after 40 weeks. BGM0504's 5 mg and 10 mg doses produced 2.05 and 2.41 percentage point reductions at 32 weeks, suggesting comparable or potentially superior efficacy in a shorter timeframe.

For the strict below-5.7% target, tirzepatide's SURPASS-2 trial reported 27.0% and 40.0% achievement rates for the 5 mg and 10 mg doses. BGM0504's combination therapy showed 29.8% and 42.9% for the respective doses at 32 weeks, indicating similar or slightly better performance in reaching normal glycemic levels.

Safety Profile Supports Clinical Viability

Both trials demonstrated favorable safety and tolerability profiles for BGM0504. In the monotherapy study, gastrointestinal adverse events—the most common side effects—were predominantly transient and mild to moderate in severity. Most resolved without intervention or with minimal symptomatic treatment. Over the full 52-week treatment period, no patients in the BGM0504 groups discontinued due to adverse events, and no severe hypoglycemia events were reported.

The combination therapy trial showed similarly reassuring safety data. Gastrointestinal side effects followed the same pattern of transient, mild-to-moderate severity. The discontinuation rate due to drug-related adverse events was just 0.54% over 52 weeks, with no severe hypoglycemia events observed.

Clinical Significance and Market Implications

Professor Ji Linong, director of the Endocrinology Department at Peking University People's Hospital and principal investigator for both Phase III trials, described the results as highly satisfactory. "The HbA1c reduction of 2.6% in monotherapy, with 93.4% of participants achieving HbA1c below 7% and 51.8% reaching normal levels below 5.7%, represents a significant advancement," Ji stated. He emphasized that in the combination therapy head-to-head comparison, BGM0504 met predefined non-inferiority criteria and achieved statistical superiority over semaglutide at both 32 and 52 weeks for the 10 mg dose, with the 5 mg dose achieving superiority in supplementary analysis at 52 weeks.

Ji also noted improvements in fasting plasma glucose and other key secondary endpoints, along with beneficial effects on weight, blood pressure, and cardiovascular metrics. "The safety profile is very encouraging," he added, expressing hope that the two studies will provide critical evidence for BGM0504's regulatory approval and offer Chinese patients an effective and safe treatment option.

BrightGene Chairman Dr. Yuan Jiandong framed the drug's potential within the evolving paradigm of diabetes management. "The concept of chronic disease management for adult diabetes in China continues to upgrade," Yuan explained. "It's no longer sufficient to focus solely on blood glucose control. The shift is toward comprehensive management that balances cardiovascular metabolic improvement, complication risk reduction, and long-term quality of life enhancement."

Yuan emphasized the value proposition: "If a drug can simultaneously improve weight, blood pressure, blood lipids, and other key metabolic indicators, it will bring entirely new value to long-term disease management." He announced that BrightGene will accelerate BGM0504's new drug application filing, expressing hope that this innovative peptide drug will benefit patients soon and fulfill the company's vision of leveraging innovative pharmaceuticals to enhance chronic disease management.

Regulatory and Commercial Outlook

The Phase III results position BGM0504 for potential regulatory submission in China. If approved, the drug would enter a competitive but rapidly expanding market. China's diabetes patient population exceeds 140 million, making it the world's largest diabetes market. The emergence of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists has transformed treatment paradigms, with patients and physicians increasingly prioritizing drugs that offer glycemic control alongside weight management and cardiovascular benefits.

BrightGene's ability to demonstrate numerical superiority over established therapies in cross-study comparisons, combined with direct head-to-head superiority over semaglutide, provides a compelling foundation for market positioning. The company's stated commitment to accelerating the new drug application suggests an aggressive timeline toward commercialization.

Whether BGM0504 can replicate the commercial success of tirzepatide and semaglutide in the Chinese market—and potentially beyond—will depend on regulatory approval, pricing strategy, manufacturing scale-up, and competitive dynamics. But for now, the clinical data have positioned BrightGene's candidate as a serious contender in the global diabetes treatment landscape.

Data Sources:

[1] Tirzepatide (Eli Lilly) SURPASS-CN-MONO study. Yin Y, Ma J, Liu D, et al. Med. 2026;7:101183.

[2] Tirzepatide (Eli Lilly) SURPASS-1 study. Rosenstock J, et al. Lancet. 2021;398(10295):143–155.

[3] Semaglutide (Novo Nordisk) SUSTAIN-1 study. Sorli C, et al. Lancet Diabetes Endocrinol. 2017;5(4):251–260.

[4] Tirzepatide (Eli Lilly) SURPASS-2 study. Frías JP, et al. N Engl J Med. 2021;385:503–515.